<DOC>
	<DOCNO>NCT00645060</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody , yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A , find tumor cell carry tumor-killing substance without harm normal cell . This may effective treatment advance cancer . PURPOSE : This phase I trial study side effect best dose yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A treat patient advance solid tumor .</brief_summary>
	<brief_title>Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - To establish maximum tolerate dose yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A describe toxicity dose study . - To estimate radiation dos whole body , normal organ , tumor serial nuclear image study intravenous infusion yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A . OUTLINE : This dose-escalation study yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A ( MOAB M5A ) . - Biodistribution : Patients receive indium In 111 radiolabeled anti-CEA MOAB M5A IV 30 minute . Patients undergo serial nuclear scan , single photon emission compute tomography ( SPECT ) , blood urine sample 1 week estimate absorb radiation dose tumor , normal organ ( i.e. , liver , lung , kidney , bone marrow ) , whole body . - Treatment : No 2 week later , patient adequate biodistribution receive yttrium Y 90 DOTA anti-CEA MOAB M5A IV 30 minute day 1 . Patients undergo serial nuclear scan , SPECT , blood urine sample 1 week estimate absorb radiation dose tumor , normal organ ( i.e. , liver , lung , kidney , bone marrow ) , whole body . Treatment repeat every 6-10 week 2 course absence disease progression unacceptable toxicity . Blood urine sample collect periodically analysis total activity radiometric high performance liquid chromatography acquire data antibody metabolism pharmacokinetics . After completion study treatment , patient follow every 3 month 6 month .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor standard effective treatment available Patients refuse available standard noncurative treatment may also eligible Tumors must produce CEA document either elevate serum CEA upper limit normal ( ULN ) immunohistochemical ( IHC ) method Positive CEA IHC stain determine 30 % tumor cell intensity 2+ great Measurable disease Estimated &lt; 1/3 liver involvement tumor involve liver No brain leptomeningeal involvement cancer PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy ≥ 3 month WBC ≥ 4,000/μL ANC ≥ 1,500/μL Platelet count ≥ 125,000/μL Creatinine ≤ 1.5 mg/dL and/or creatinine clearance &gt; 60 mL/min Bilirubin ≤ 1.5 mg/dL ALT AST ≤ 2 time ULN Negative pregnancy test Fertile patient must use effective contraception Patients currently treat severe infection recover intercurrent illness ( poorly control diabetes hypertension ) ineligible recovery deem complete investigator Serum antiantibody test must negative human antihumanized antibody ( patient receive prior monoclonal antibody ) Serum HIVnegative Serum hepatitis B antigen hepatitis C antibodynegative PRIOR CONCURRENT THERAPY : At least 4 week since prior radiotherapy , immunotherapy , chemotherapy ( 6 week mitomycin C nitrosoureas ) recover Recovered prior major surgery No prior radiotherapy &gt; 50 % bone marrow No concurrent chemotherapy , radiotherapy , immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>